Health Care & Life Sciences » Biotechnology | Blueprint Medicines Corp.

Blueprint Medicines Corp.

Blueprint Medicines Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
43.89 M
Public Float
36.97 M
Blueprint Medicines Corp.
Stock Exchange NASDAQ Stock Market
EPS
$6.08
Market Cap
$4.68 B
Shares Outstanding
48.85 M
Public Float
42.04 M

Profile

Address
45 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.blueprintmedicines.com
Updated 07/08/2019
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.

Financials

View All

Jeffrey W. Albers
President, Chief Executive Officer & Director
Daniel S. Lynch
Director